Centene sunitinib Coverage Update & Prior Auth

Coverage and Medical Necessity Criteria

Initial Therapy - GIST

Initial approval — Gastrointestinal stromal tumor (GIST): Covered when ALL of the following are met

GIST initial: 1) Diagnosis of gastrointestinal stromal tumor (GIST); 2) Prescribed by or in consultation with an oncologist; 3) Age > 18 years; 4) Request is for one of: a) disease progression on or intolerance to imatinib as single-agent therapy; b) combination therapy with everolimus for unresectable, tumor rupture, recurrent/progressive, or metastatic disease after progression on approved therapies (off-label); c) SDH-deficient disease as single-agent therapy (off-label); 5) For Sutent requests, member must use generic sunitinib unless contraindicated or clinically significant adverse effects are experienced; 6) Dose does not exceed 50 mg/day (4 weeks on/2 weeks off) unless co-administered with a CYP3A4 inducer (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort) in which case dose does not exceed 87.5 mg per 4 weeks on/2 weeks off; 7) Prescribed regimen must be FDA-approved or recommended by NCCN or supported by practice guidelines/peer-reviewed literature (prescriber must submit supporting evidence).

From Initial Approval GIST section

Initial Therapy - RCC

Initial approval — Renal cell carcinoma (RCC): Covered when ALL of the following are met

RCC initial: 1) Diagnosis of renal cell carcinoma (RCC); 2) Prescribed by or in consultation with an oncologist; 3) Age >= 18 years; 4) Indication is one of: a) adjuvant therapy post-nephrectomy for clear cell histology limited to up to nine 6-week cycles (one 6-week cycle = 4 weeks on/2 weeks off); or b) treatment of relapsed or stage IV RCC; 5) For Sutent requests, member must use generic sunitinib unless contraindicated or clinically significant adverse effects are experienced; 6) Dose does not exceed 50 mg/day (4 weeks on/2 weeks off) or up to 87.5 mg/day if co-administered with a CYP3A4 inducer; 7) Prescribed regimen must be FDA-approved or recommended by NCCN or supported by practice guidelines/peer-reviewed literature (prescriber must submit supporting evidence).

From Initial Approval RCC section

Initial Therapy - pNET

Initial approval — Pancreatic neuroendocrine tumor (pNET): Covered when ALL of the following are met

pNET initial: 1) Diagnosis of well-differentiated pancreatic neuroendocrine tumor (pNET); 2) Prescribed by or in consultation with an oncologist; 3) Age >= 18 years; 4) Disease is unresectable, recurrent, advanced, or metastatic; 5) For Sutent requests, member must use generic sunitinib unless contraindicated or clinically significant adverse effects are experienced; 6) Dose does not exceed 37.5 mg/day (standard) or up to 62.5 mg/day if co-administered with a CYP3A4 inducer; 7) Prescribed regimen must be FDA-approved or recommended by NCCN or supported by practice guidelines/peer-reviewed literature (prescriber must submit supporting evidence).

From Initial Approval pNET section; 2Q2025 clarifies well-differentiated requirement and removal of single-agent restriction

Initial Therapy - NCCN Compendium Indications (off-label)

Initial approval — NCCN Compendium (off-label) indications: Covered when ALL of the following are met

NCCN off-label initial: 1) Diagnosis is one of the listed NCCN Compendium tumors (examples include chordoma; angiosarcoma; alveolar soft part sarcoma; solitary fibrous tumor; thymic carcinoma; extraskeletal myxoid chondrosarcoma; oncocytic [Hurthle cell] carcinoma when not amenable to RAI and other options unavailable; medullary thyroid carcinoma for recurrent/persistent/metastatic disease when other options unavailable; myeloid/lymphoid or mixed phenotype neoplasms with eosinophilia with FLT3 rearrangement in chronic or blast phase; pheochromocytoma/paraganglioma as described; and others per NCCN); 2) Prescribed by or in consultation with an oncologist; 3) Age >= 18 years; 4) Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines/peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence); 5) For Sutent requests, member must use generic sunitinib unless contraindicated or clinically significant adverse effects are experienced.

From NCCN Compendium Indications sections; 2Q2025 updates added extraskeletal myxoid chondrosarcoma and other NCCN-aligned changes

Covered Indications (FDA and NCCN-supported off-label uses)

Covered when meeting FDA or NCCN-supported indication-specific criteria (select examples summarized from policy updates):

Indications summary: Policy covers FDA-labeled and NCCN-supported indications including GIST (after imatinib failure/intolerance and specified NCCN expansions), RCC (including adjuvant clear cell with nine 6-week cycle limit), pNET (well-differentiated), selected thyroid carcinomas (e.g., oncocytic/Hurthle cell and medullary in specific contexts), myeloid/lymphoid or mixed phenotype neoplasms with eosinophilia (chronic or blast phase with FLT3 rearrangement), alveolar soft part sarcoma, pheochromocytoma/paraganglioma, extraskeletal myxoid chondrosarcoma, and other NCCN-compendium supported uses.

See full policy for indication-specific prior therapy, histology, or cycle/duration requirements.

Non-FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (commercial: CP.CPA.09; Health Insurance Marketplace: HIM.PA.154; Medicaid: CP.PMN.53) or other evidence of coverage documents.

Certain off‑label uses previously listed in this policy have been removed or narrowed to align with updated NCCN Compendium guidance and internal line-of-business rules. Examples include adjustment of second‑line designations and refinements to indication-specific requirements; requests that no longer match the updated NCCN-supported uses may be excluded from coverage.

Requests for non‑FDA uses that are not addressed by this policy or that lack sufficient supporting evidence per the off‑label use policies are considered not authorized. When coverage for an off‑label indication is requested, prescribers must supply guideline or peer‑reviewed literature support as required by the criteria.

Therapy requests that do not meet the policy's specified requirements — including the stated indication, required histology or mutation status, prior therapy documentation, dosing limits, or duration/cycle limits — will be considered not medically necessary / not covered and may be denied.

Initial Authorization Criteria and Dosing

Initial Therapy Criteria

Initial authorization criteria vary by diagnosis; prescriber must be an oncologist or consult and provide supporting evidence for off-label uses. Covered when ALL of the applicable following are met:

Top-level initial authorization

See diagnosis-specific criteria: Refer to Initial Therapy - GIST; Initial Therapy - RCC; Initial Therapy - pNET; Initial Therapy - NCCN Compendium Indications for the detailed, diagnosis-specific requirements.

Continuation (Renewal) Authorization Criteria

Continuation Therapy

Continuation therapy: Covered when ALL of the following are met

Continuation: 1) Member is currently receiving sunitinib via the Centene benefit or documentation supports current use for a covered indication and member has received at least 30 days of therapy; 2) Member is responding positively to therapy (clinical benefit documented); 3) For adjuvant RCC, member has not completed nine 6-week cycles; 4) For Sutent requests, member must use generic sunitinib unless contraindicated or clinically significant adverse effects are experienced; 5) If request is for a dose increase, the new dose must not exceed indication-specific maximums (50 mg/day standard; up to 87.5 mg/day with CYP3A4 inducer for GIST/RCC; 37.5 mg/day standard for pNET or up to 62.5 mg/day with CYP3A4 inducer) or must be supported by practice guidelines/peer-reviewed literature (prescriber must submit supporting evidence).

From Continued Therapy section; Medicaid/HIM continued approval duration modified per 2Q2025

Continuation Therapy

Continuation approvals follow initial authorization parameters with plan-specific duration limits and documented ongoing benefit

Continuation approvals:

Prescriber Requirements and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for sunitinib (Sutent) requests. The provider must document that all approval criteria are met; approval duration will follow the member's line of business rules and applicable policy duration limits.

Prior authorization required; approval duration follows line of business rules
For brand Sutent requests, use of generic sunitinib is required unless contraindicated or clinically significant adverse effects are experienced

Denial Risk

Off‑Label Use — Denial Risk Without Supporting Evidence

Requests for non–FDA approved (off‑label) indications that are not addressed in this policy are not authorized unless the prescriber submits sufficient documentation supporting efficacy and safety consistent with the plan's off‑label use policies (e.g., CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, CP.PMN.53 for Medicaid) or other evidence of coverage documents. Off‑label uses supported by NCCN or peer‑reviewed literature and accompanied by supporting evidence may be considered.

Product Availability, Dosing, and Coding

Product availability / dosageNDC

NDC	Capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg

inv-12: RCC adjuvant cycles — Limit: nine 6-week cycles

Adjuvant RCC cycle limitLimited to nine 6-week cycles (one cycle = 4 weeks on/2 weeks off)

Applicable indicationAdjuvant therapy post-nephrectomy for clear cell renal cell carcinoma

Dose contextStandard RCC dosing 50 mg/day PO 4 weeks on/2 weeks off (higher cumulative dosing guidance applies if co-administered with CYP3A4 inducers)

Step Therapy and Prior Treatment Requirements

Therapeutic alternative	Indication / notes	Prior authorization
imatinib (Gleevec)	Listed as a preferred alternative for GIST; dosing: 400 mg/day (may be titrated up to 400 mg BID; max 800 mg/day)	Prior authorization may be required for imatinib
ripretinib (Qinlock)	Listed as an alternative for GIST per Appendix B
regorafenib (Stivarga)	Listed as an alternative for GIST; dosing example: 160 mg PO QD for first 21 days of each 28-day cycle
dasatinib (Sprycel)	Listed among therapeutic alternatives in Appendix B (alternative contexts per indication)

Indication	Required prior therapy / documentation	Notes
Gastrointestinal stromal tumor (GIST)	Documentation of disease progression on or intolerance to imatinib (single-agent) OR documentation supporting SDH-deficient disease or need for combination therapy with everolimus where applicable	Prescriber must be an oncologist or consult; member must use generic sunitinib unless contraindicated; dosing limits apply (50 mg/day standard)
Renal cell carcinoma (RCC)	For adjuvant clear cell: documentation supporting post‑nephrectomy high‑risk disease; for relapsed/stage IV: standard staging documentation; when prior therapy is recommended per NCCN, document failure or inappropriateness of prior FDA‑approved therapies	Adjuvant RCC limited to nine 6‑week cycles; prescriber requirement and generic sunitinib requirement apply
Pancreatic neuroendocrine tumor (pNET)	Documentation that tumor is well‑differentiated and disease is unresectable, recurrent, advanced, or metastatic; prior single‑agent restriction removed (per 2Q 2025)	Prescriber must be an oncologist or consult; generic sunitinib preferred; dosing: standard 37.5 mg/day unless CYP3A4 inducer co‑administered
NCCN Compendium off‑label indications	Documentation per NCCN Compendium: diagnosis, supportive evidence (guidelines or peer‑reviewed literature), and when specified, failure of or inappropriateness of prior FDA‑approved therapies (e.g., certain thyroid carcinoma contexts)	Prescriber must be an oncologist or consult; use generic sunitinib unless contraindicated; dose must be within FDA max for any FDA‑approved indication or supported by literature

Quantity and Dispensing Limits

inv-33: sunitinib capsules — Quantity limits per prescribing regimen

Quantity limits summaryQuantity limits follow the prescribing regimen and available capsule strengths (12.5, 25, 37.5, 50 mg)

Per-regimen determinationTotal quantity authorized is calculated based on the approved dosing schedule for the indication (e.g., 4 weeks on/2 weeks off cycles for many regimens)

Strengths availableCapsule strengths: 12.5 mg, 25 mg, 37.5 mg, 50 mg

Definitions and Indication Notes

inv-22: gastrointestinal stromal tumor — definition/key term

TermGastrointestinal stromal tumor (GIST)

AbbreviationGIST

Context in policyListed as an FDA-approved indication with specific initial and continuation criteria (e.g., progression on or intolerance to imatinib)

inv-23: pancreatic neuroendocrine tumor — definition/key term

TermPancreatic neuroendocrine tumor (pNET)

AbbreviationpNET

Policy notesPolicy requires pNET to be well-differentiated (updated in 2Q 2025); pNET is an FDA-covered indication with defined dosing

Site of Care and Administration

Note

Oral drug — outpatient/home site‑of‑care

Oral administration; site‑of‑care defaults to outpatient/ambulatory (home) management per the prescriber's clinical judgment.

Sunitinib is an oral agent — administration and site‑of‑care decisions are made by the prescriber.

Background and Drug Overview

Sunitinib (Sutent) is an oral multi‑target tyrosine kinase inhibitor indicated and used across multiple adult malignancies. The policy covers FDA‑labeled uses such as treatment of advanced renal cell carcinoma, adjuvant therapy for high‑risk clear cell RCC (limited per policy to nine 6‑week cycles), treatment of gastrointestinal stromal tumor after progression on or intolerance to imatinib, and therapy for progressive, well‑differentiated pancreatic neuroendocrine tumors. The policy also allows select NCCN Compendium–supported off‑label indications when prescriber documentation and evidence requirements are met; the 2Q 2025 review expanded criteria to explicitly include generic sunitinib and updated multiple NCCN‑aligned indication and duration rules.

OpenPayer

Sunitinib (Sutent) coverage and authorization